DOI: 10.5472/marumj.2070752 ISSN: 1019-1941

Real-world plasma-based next-generation sequencing findings in metastatic lung adenocarcinoma: a single-center retrospective study

Erkam Kocaaslan, Emir Göçer, Fırat Akagündüz, Ahmet Demirel, Mustafa Alperen Tunç, Burak Paçacı, Yeşim Ağyol, Pınar Erel, Ali Kaan Güren, Osman Köstek, Vedat Bayoğlu
Show PDF Cite
Objective: To determine the frequency and distribution of genomic alterations detected by plasma-based next-generation sequencing(NGS) in metastatic lung adenocarcinoma in a real-world setting.Patients and Methods: This retrospective single-center study included 76 patients with histologically confirmed metastatic lungadenocarcinoma who underwent plasma circulating tumor DNA (ctDNA) NGS between March 2021 and July 2024. Targetedsequencing was performed using a 28-gene panel. Genomic alterations were classified as actionable according to current clinicalguidelines. Concordance with available tissue-based molecular testing was evaluated in the internal cohort.Results: At least one genomic alteration was detected in 43/76 patients (56.6%). Among NGS-positive patients, 19/43 (44.2%) had ≥2alterations. Actionable alterations were identified in 24/76 patients (31.6%;55.8% of NGS-positive cases). The most frequently alteredgenes were TP53 (35.5%), EGFR (18.4%), and KRAS (13.2%). In an exploratory survival analysis of internal NGS-positive patients(n=19), median overall survival (OS) was 27 vs 29 months for patients with and without actionable alterations, respectively (p=0.94).Conclusion: Plasma-based NGS identifies clinically relevant genomic alterations in metastatic lung adenocarcinoma and complementstissue-based molecular testing in routine practice.

More from our Archive